PRODUCT · EVIDENCE PACK
An 8–12 page report per target with reproducible scripts, built from public data. No client data needed. For licensing, project initiation and indications.
A standard-format report on a single target. It answers one question: in which indication does this target have a case, and where are the risks?
Every analysis uses public databases, so we can start without any of your internal data. Each pack runs 8–12 pages, comes with reproducible scripts, and every number traces back to its original data source.
01
Once a partner's scientists have reviewed the molecule, the next question is usually "why this indication?" The evidence pack gives them a document with clear methods and scripts that their own team can check. It is written to sit in a data room.
02
An initiation review needs to know where the target is differentially expressed, where the normal-tissue risks are, and how it relates to immunity and prognosis. The pack puts those answers in one report.
03
The target is set and the indication is open, or you're weighing a second or third indication. With one format, results across cancer types can be compared directly.
WHAT'S INSIDE
8–12 pages per target, with reproducible scripts.
The pack uses public databases only. We don't need your sequences or experimental data, and none of your clients' data is involved.
In practice, a first project doesn't have to wait for internal data approvals or transfers.
Answers
Analyses of bulk data such as TCGA answer disease-side questions: in which cancer types the target is expressed above normal tissue, by how much, which normal organs also express it, what immune infiltration looks like in high-expressing patients, and whether expression tracks with prognosis. The single-cell layer goes one step further and shows which cell types the expression comes from.
Does not answer
It can't establish properties of the molecule itself, such as epitope or affinity. Each report states the scope of every conclusion. We don't claim more than public data can support.
TIMELINE
About 4–6 weeks, depending on scope. A typical schedule:
Week 1: agree the format with your BD or project team. What does the other side ask most often? The report is built around those questions.
Weeks 2–4: analysis.
Week 5: internal review and biological interpretation.
Week 6: delivery, with a results walkthrough.
A pilot starts at 3 targets: three evidence packs in the same format.
We suggest targets whose lead indications don't overlap. That tests whether one method gives consistent, comparable results across different cancer types.
Before the pilot starts, we agree on scope, deliverable format and how the work will be accepted.
Once the pilot has fixed the format and methods, larger target sets follow the same process. Every report uses the same format and methods and comes with scripts, so results are comparable across targets and the other side can check where each number comes from.
Scope and pricing for larger sets are discussed after the pilot, based on the number of targets.
In a free 30-minute consultation, tell us which targets you're looking at and what the pack is for: licensing, initiation or indication selection. We'll confirm whether public data can support it and suggest a pilot scope.
